Our Commitment to Patients
At Plexium, patients are at the center of everything we do. As a clinical-stage company, we are conducting carefully designed clinical studies to evaluate investigational therapies that aim to address serious diseases with significant unmet medical need.
Clinical studies are an essential part of how new therapies are developed. They help researchers understand the safety, tolerability, and potential effectiveness of investigational treatments, while advancing medical knowledge for future patients.
SMARCA2
PLX-61639 is an oral SMARCA2-selective direct degrader in development to treat patients with SMARCA4 mutated locally advanced or metastatic solid tumors who have failed available, approved therapies. The study is enrolling adult participants with certain advanced or metastatic cancers who meet specific eligibility criteria.
For more information, please visit clinicaltrials.org.
IKZF2
PLX-4545 is an oral IKZF2-selective molecular glue degrader developed as a monotherapy and in combination to improve clinical responses to immune checkpoint inhibitors across multiple solid tumor types. PLX-4545 was evaluated in healthy volunteers to assess the safety, tolerability (how well an individual can tolerate a drug), pharmacokinetics (how a drug moves into, through and out of the body) and pharmacodynamics (the effect of a drug on the body) of single and multiple ascending doses.
For more information, please visit anzctr.org.
Expanded Access Summary
At Plexium, our mission is to bring transformative targeted protein degradation therapies to patients with serious diseases who have limited or no treatment options. We are driven by the belief that scientific innovation can make a meaningful difference in patients’ lives, and we are working with urgency to advance our investigational medicines through clinical development as safely and efficiently as possible.
We recognize that some patients and physicians may be interested in accessing investigational medicines outside of a clinical trial. At this time, participation in one of Plexium’s clinical trials is the only way to access our investigational medicines, including PLX-61639. We believe this approach ensures that patients receive the highest level of safety oversight and that robust data can be collected to support potential regulatory approval.
Learn More
Information about our ongoing and upcoming clinical trials can be found at ClinicalTrials.gov by searching for “Plexium.” Physicians or patients seeking more information may contact clinicaltrials@plexium.com.